Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR4 | P46093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784138 | 0.82 | CDK1 (0.36) | — | |
| SCHEMBL22133761 | 0.80 | PKM (0.36) | — | |
| SCHEMBL12946398 | 0.76 | ADORA2A (0.40) | — | |
| SCHEMBL789756 | 0.75 | HRH4 (0.37) | — | |
| SCHEMBL25049214 | 0.73 | — | — | |
| SCHEMBL19822712 | 0.73 | — | — | |
| SCHEMBL23107319 | 0.72 | CCR1 (0.42) | — | |
| SCHEMBL16884033 | 0.70 | PDE10A (0.31) | — | |
| SCHEMBL19711586 | 0.70 | KMT2A (0.34) | — | |
| SCHEMBL15187555 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
| US-20180194793-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2018-07-12 | — | — | US | disclosed |
| US-20180155384-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9932363-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-03-22 | — | — | US | disclosed |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2018-02-15 | — | — | US | disclosed |
| US-9890188-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9862743-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV | 2015-01-01 | — | — | US | disclosed |
| US-8877731-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100240604-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20090181921-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080207554-A1 | 2-5A Analogs and their Methods of Use | ALIOS BIOPHARMA, INC. (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | NTPCR, NT5C2, PNP | GPR4 2964/4885 |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | GPR4 972/4885 |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | GPR4 1353/4885 |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | GPR4 4645/4885 |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | GPR4 2343/4885 |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | GPR4 4645/4885 |
| US-20090181921-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | RNASEL, RNASE1, RNASEH1 | GPR4 4509/4885 |
| US-20100240604-A1 | PROTECTED NUCLEOTIDE ANALOGS | PNP, NTPCR, TYMP | GPR4 2833/4885 |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | GPR4 1653/4885 |
| US-20180194793-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | GPR4 1670/4885 |
| US-20180155384-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | GPR4 2293/4885 |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | PNP, TYMP, NTPCR | GPR4 2400/4885 |
| US-20080207554-A1 | 2-5A Analogs and their Methods of Use | RNASEL, RNASE1, RNASEH1 | GPR4 4794/4885 |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | GPR4 814/4885 |
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | GPR4 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.